Clinical trials: Patients With Advanced Solid Tumors
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Advanced Solid Tumors
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
- Trial name
- NCT05944224
- Testing
- SPH4336, Cadonilimab
- Where
- 16 sites in China
- Volunteers
- 63 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Cancer
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer.
- Trial name
- NCT00606879
- Testing
- SGX523 Capsules
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- SGX Pharmaceuticals, Inc.
Advanced Solid Tumor
Study of LM-302 in Patients With Advance Solid Tumors
A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
- Trial name
- NCT05161390
- Testing
- LM-302 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Advanced Solid Tumors
FPT155 in Patients With Advanced Solid Tumors
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in patients with advanced solid tumors.
- Trial name
- FPT155-001 (NCT04074759)
- Testing
- FPT155, pembrolizumab
- Where
- 12 sites in Australia, South Korea
- Volunteers
- 80 people
- Sponsor
- Five Prime Therapeutics, Inc.
Solid Tumor
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05494762
- Testing
- BGB-B167, Tislelizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- BeiGene
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more tumor cells.
- Trial name
- NCT00290680
- Testing
- bortezomib, celecoxib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Cancer
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
This phase I study will characterize the safety, tolerability, and maximum tolerated dose and dose-limiting toxicity of weekly bolus Topotecan when administered in combination with to different dosing regimens of docetaxel.
- Trial name
- NCT00193570
- Testing
- Topotecan, Docetaxel
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Adult Solid Neoplasm
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
This phase I trial is studying the side effects and best dose of interferon alfa-2b when given together with vaccine therapy and GM-CSF in treating patients with locally advanced or metastatic cancer that makes CEA.
- Trial name
- NCT00217373
- Testing
- Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Colorectal Cancer
Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy
This is a prospective observational cohort study conducted at Fundación CTIC in Bogotá, Colombia. It characterizes the oral, fecal and intratumoral microbiome of Colombian adults with advanced solid tumors (gastric, colorectal…
- Conditions
- Gastric Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer
- Trial name
- ATLAS (NCT07676461)
- Testing
- First-line immunotherapy (immune checkpoint inhibitors), INVIMA-approved, standard of care
- Where
- Colombia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.
- Trial name
- NCT04423380
- Testing
- SH3051 capsule treatment
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Tumors, Non-Hodgkins's Lymphoma
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy.
- Trial name
- NCT00298779
- Testing
- omeprazole and bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer, Solid Tumor, Adult
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab.
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma
- Trial name
- KEYNOTE-E12 (NCT04443088)
- Testing
- INV-1120, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
- Trial name
- NCT06687070
- Testing
- APG -2449, PLD
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced or Metastatic Solid Tumors
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
- Trial name
- NCT04586270
- Testing
- TAS0612
- Where
- 4 sites in United States, France
- Volunteers
- 47 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors
Study of ZGGS15 in Patients With Advanced Solid Tumors
This is a multi-center, open-label, Phase 1 clinical study of ZGGS15 for the treatment of patients with advanced solid tumors.
- Trial name
- NCT05864573
- Testing
- ZGGS15
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Solid Tumors, Soft-tissue Sarcoma
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Assessment of the efficacy and safety of JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma and advanced breast cancer, once the Maximum Tolerated Dose have been determined (phase I trial).
- Conditions
- Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
- Trial name
- METROmaJX (NCT02630368)
- Testing
- Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide
- Where
- France
- Volunteers
- 197 people
- Sponsor
- Institut Bergonié
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.